By M. Marin
Focused on opportunities in the areas of next-generation diagnostics, drug delivery, and drug development …
XPhyto Therapeutics (OTC:XPHYF) is a bioscience accelerator focused on opportunities in the areas of next-generation diagnostics, drug delivery, and drug development. The company recently launched a rapid point-of-care COVID-19 PCR system in Europe and is developing a pipeline of low-cost biosensor screening tests.
XPHYF forged a commercial partnership with German-based 3a-diagnostics GmbH to jointly develop and launch oral diagnostic products, beginning with a COVID-19 rapid test. Subsequently, the company announced that it had signed a definitive agreement to acquire 3a on July 20, 2021. XPhyto is acquiring 3a-diagnostics in order to commercialize diagnostic tests in the 3a-diagnotics pipeline for the detection of infectious diseases. The company’s diagnostics goal is to develop rapid, low-cost pathogen screening tests for pandemic and oral health applications to launch in European and other markets.
… With positive initial COVID-19 PCR test launch
XPhyto has a robust pipeline of products and assets that are under development (see below), with many close to expected commercial launch. XPhyto is optimistic about its recently-launched COVID-19 PCR test and other tests. As the rebound in travel accelerates, the need for reliable and rapid PCR testing to monitor the pandemic is expected to rise and XPhyto believes its COVID test has several competitive advantages compared to others, including rapid turnaround, accuracy throughout the life of the virus with high sensitivity and specificity, notably when the person is pre-symptomatic or asymptomatic.
The company’s PCR testing system allows for moderate- to low-volume testing at cost effective price points, which makes XPhyto’s test economical for smaller testing centers, as well as for larger venues, as infection rates fluctuate. The company anticipates that its COVID test will have strong adoption.
Leveraging expertise & leveraging drug delivery platform
The company also intends to leverage the oral dissolvable drug (ODF) formulations and other delivery mechanisms and cannabinoid and psychedelic expertise and relationships that it has formed to develop and launch innovative medicinal programs. The company also intends to pursue psychedelic drug delivery and API production opportunities and has formed several collaborations towards this goal.
XPhyto is developing a TDS patch with rotigotine as the active pharmaceutical ingredient, and announced last year that its subsidiary Vektor had finalized the formula for its novel TDS. XPhyto completed a human bioavailability pilot study of its Rotigotine TDS patch for Parkinson’s disease in March 2021. Based on the positive results of the study, the company is advancing the Rotigotine development program to a pivotal human trial.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $40,000 annually for these services. Full Disclaimer HERE.